The company received FDA approval for Natazia in May 2010 for the prevention of pregnancy.
The contraceptive efficacy of Natazia has not been evaluated in women with a body mass index (BMI) greater than 30kg/m2, the company said.
The approval was based on two identically-designed, multicenter, double-blind, randomized, placebo controlled trials.
Patients with HMB who were treated with Natazia achieved a statistically significant reduction in menstrual blood loss compared with patients in the placebo group (p<0.0001 for both studies).
Bayer HealthCare vice president and US Medical Affairs head said Natazia represents a new treatment approach for appropriate women with heavy menstrual bleeding.